{"id":"placebo-soc","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a control arm designation rather than an active drug. It represents the baseline treatment (standard of care) plus an inert placebo, used in phase 3 trials to establish efficacy and safety of the experimental agent by comparison. The specific mechanism depends entirely on what the standard of care regimen includes for the indication being studied.","oneSentence":"Placebo combined with standard of care provides a control comparator in clinical trials to assess the incremental benefit of an investigational therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:34.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05366855","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","status":"TERMINATED","sponsor":"Vanda Pharmaceuticals","startDate":"2022-04-21","conditions":"Generalized Pustular Psoriasis","enrollment":42},{"nctId":"NCT06022822","phase":"PHASE2","title":"Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-12","conditions":"Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05419011","phase":"PHASE2","title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-08","conditions":"Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome","enrollment":186},{"nctId":"NCT07410507","phase":"PHASE2","title":"A Study of Brenipatide in Adult Participants With Schizophrenia","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-10","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT07492875","phase":"PHASE3","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis","enrollment":10},{"nctId":"NCT07276581","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT07412756","phase":"PHASE3","title":"A Study of Brenipatide in Adult Participants With Major Depressive Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-09","conditions":"Depressive Disorder, Major","enrollment":1000},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT06517758","phase":"PHASE3","title":"A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-31","conditions":"Generalized Myasthenia Gravis","enrollment":146},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT07286175","phase":"PHASE2","title":"A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-24","conditions":"Bipolar Disorder","enrollment":400},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT07207811","phase":"PHASE3","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-10-02","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":1280},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT05126277","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-14","conditions":"Lupus Nephritis","enrollment":462},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT05753007","phase":"PHASE2","title":"A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients","status":"TERMINATED","sponsor":"Mclean Hospital","startDate":"2024-02-15","conditions":"Glioblastoma","enrollment":2},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT06979375","phase":"PHASE2","title":"A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-30","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT07301034","phase":"PHASE3","title":"A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-12-18","conditions":"Myocardial Infarction","enrollment":332},{"nctId":"NCT06979362","phase":"PHASE2","title":"A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-27","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT07456852","phase":"PHASE1, PHASE2","title":"Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-31","conditions":"Malignant Digestive System Neoplasm","enrollment":60},{"nctId":"NCT07456033","phase":"PHASE3","title":"A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-06","conditions":"Asthma","enrollment":456},{"nctId":"NCT06982820","phase":"NA","title":"Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia","status":"RECRUITING","sponsor":"GrayMatters Health Ltd.","startDate":"2025-06-25","conditions":"Depressive Disorder, Major","enrollment":170},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07439848","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis","status":"RECRUITING","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2023-12-25","conditions":"Acute Respiratory Distress Syndrome","enrollment":15},{"nctId":"NCT07098988","phase":"PHASE2","title":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-08-01","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":107},{"nctId":"NCT05123755","phase":"PHASE2","title":"Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.","status":"RECRUITING","sponsor":"Vasomune Therapeutics, Inc.","startDate":"2021-12-20","conditions":"Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia","enrollment":120},{"nctId":"NCT05254990","phase":"PHASE3","title":"Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-04-27","conditions":"Infectious Pneumonia, Severe COVID-19","enrollment":414},{"nctId":"NCT05799755","phase":"PHASE4","title":"Myositis Interstitial Lung Disease Nintedanib Trial","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2023-08-01","conditions":"Myositis Associated Interstitial Lund Disease (MA-ILD)","enrollment":49},{"nctId":"NCT07235683","phase":"PHASE4","title":"Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-12-24","conditions":"CMV, Lung Transplant Recipient","enrollment":40},{"nctId":"NCT07144826","phase":"EARLY_PHASE1","title":"Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-03-09","conditions":"Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8","enrollment":161},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT04895241","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-05-25","conditions":"Lupus Erythematosus, Systemic","enrollment":548},{"nctId":"NCT07398612","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-31","conditions":"Acute Ischemic Stroke","enrollment":60},{"nctId":"NCT04485949","phase":"PHASE2","title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imvax","startDate":"2023-03-20","conditions":"Glioblastoma","enrollment":93},{"nctId":"NCT06897839","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)","status":"RECRUITING","sponsor":"Airway Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Bronchopulmonary Dysplasia","enrollment":366},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT06564207","phase":"PHASE2","title":"Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults","status":"NOT_YET_RECRUITING","sponsor":"Inova Health Care Services","startDate":"2026-08-30","conditions":"Acute Respiratory Distress Syndrome, ARDS","enrollment":40},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT06072482","phase":"PHASE4","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-02-07","conditions":"Antineutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":300},{"nctId":"NCT04961567","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-07-16","conditions":"Lupus Erythematosus, Systemic","enrollment":562},{"nctId":"NCT07373262","phase":"PHASE3","title":"Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-03-01","conditions":"ANCA-Associated Vasculitis (AAV)","enrollment":130},{"nctId":"NCT05776004","phase":"PHASE2","title":"Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2023-07-22","conditions":"Pneumonia, Bacterial","enrollment":276},{"nctId":"NCT03833154","phase":"PHASE3","title":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-03-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":724},{"nctId":"NCT07365319","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-05-18","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC","enrollment":750},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT05497284","phase":"PHASE2","title":"To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":46},{"nctId":"NCT06456567","phase":"PHASE3","title":"A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)","status":"WITHDRAWN","sponsor":"Vor Biopharma","startDate":"2024-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT05306574","phase":"PHASE3","title":"A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)","status":"TERMINATED","sponsor":"Vor Biopharma","startDate":"2022-06-20","conditions":"Systemic Lupus Erythematosus","enrollment":91},{"nctId":"NCT06208215","phase":"PHASE3","title":"RZ358 Treatment for Congenital Hyperinsulinism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rezolute","startDate":"2024-01-11","conditions":"Congenital Hyperinsulinism","enrollment":56},{"nctId":"NCT06202521","phase":"PHASE2","title":"CX-4945 in Viral Community Acquired Pneumonia","status":"TERMINATED","sponsor":"Senhwa Biosciences, Inc.","startDate":"2024-03-20","conditions":"Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia","enrollment":45},{"nctId":"NCT07276204","phase":"PHASE2","title":"Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)","status":"NOT_YET_RECRUITING","sponsor":"Southern California Institute for Research and Education","startDate":"2026-03-31","conditions":"MASH - Metabolic Dysfunction-Associated Steatohepatitis","enrollment":70},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT05948592","phase":"PHASE2","title":"Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection","status":"COMPLETED","sponsor":"Technophage, SA","startDate":"2023-11-08","conditions":"Diabetic Foot Infection","enrollment":76},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT05274750","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-22","conditions":"Nasal Polyps","enrollment":276},{"nctId":"NCT04393038","phase":"PHASE2, PHASE3","title":"ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","status":"TERMINATED","sponsor":"Abivax S.A.","startDate":"2020-07-01","conditions":"COVID-19","enrollment":509},{"nctId":"NCT07177339","phase":"PHASE3","title":"eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1196},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT04250922","phase":"PHASE2, PHASE3","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laminar Pharmaceuticals","startDate":"2019-12-01","conditions":"Primary Glioblastoma, Glioblastoma Multiforme","enrollment":144},{"nctId":"NCT05263934","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-07-14","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":163},{"nctId":"NCT06694701","phase":"PHASE2","title":"Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2025-03-22","conditions":"Sepsis","enrollment":75},{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT04060277","phase":"PHASE2","title":"Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-11-27","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT07227649","phase":"PHASE2","title":"NAC-REPAIR for Post-surgical Pain","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-01-15","conditions":"Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome","enrollment":80},{"nctId":"NCT06205589","phase":"PHASE2","title":"Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB","status":"NOT_YET_RECRUITING","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2026-02-15","conditions":"Tuberculosis, Pulmonary","enrollment":1500},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT05496868","phase":"PHASE2","title":"Add-on Reparixin in Adult Patients With ARDS","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-12-06","conditions":"Acute Respiratory Distress Syndrome, Adult","enrollment":66},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT06061081","phase":"PHASE2","title":"A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2023-12-21","conditions":"HIV Infections","enrollment":21},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":87},{"nctId":"NCT06729606","phase":"PHASE3","title":"Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":471},{"nctId":"NCT05559099","phase":"PHASE2","title":"Tecovirimat for Treatment of Monkeypox Virus","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-10","conditions":"Monkeypox","enrollment":597},{"nctId":"NCT06959095","phase":"PHASE3","title":"Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":981},{"nctId":"NCT03656562","phase":"PHASE2","title":"Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-19","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":107},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT07207057","phase":"PHASE3","title":"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-09-12","conditions":"Parkinsons Disease (PD)","enrollment":1200},{"nctId":"NCT07174492","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-01-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":412},{"nctId":"NCT04582136","phase":"PHASE3","title":"Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2021-03-04","conditions":"Systemic Lupus Erythematosus","enrollment":146},{"nctId":"NCT04762017","phase":"PHASE2","title":"OCS-05 in Patients With Optic Neuritis","status":"COMPLETED","sponsor":"Oculis","startDate":"2021-02-10","conditions":"Optic Neuritis","enrollment":36},{"nctId":"NCT06925061","phase":"PHASE2","title":"Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease","status":"RECRUITING","sponsor":"Madeleine Bezault","startDate":"2025-03-31","conditions":"Crohn Disease (CD)","enrollment":80},{"nctId":"NCT05335928","phase":"PHASE3","title":"Abatacept in Immune Checkpoint Inhibitor Myocarditis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-07-02","conditions":"Myocarditis Acute, Cancer","enrollment":390},{"nctId":"NCT06330584","phase":"PHASE2","title":"Administration of Intranasal Midazolam for Anxiety in Palliative Care","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-12-20","conditions":"Anxiety, Acute Anxiety, Palliative Care","enrollment":36},{"nctId":"NCT05281523","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-18","conditions":"Nasal Polyps","enrollment":264},{"nctId":"NCT05132569","phase":"PHASE3","title":"Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-12-03","conditions":"Myasthenia Gravis","enrollment":6},{"nctId":"NCT06721585","phase":"","title":"Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-07-10","conditions":"Mpox (Monkeypox)","enrollment":328},{"nctId":"NCT04815083","phase":"PHASE3","title":"Fluorescence Imaging of Carcinoma During Breast Conserving Surgery","status":"TERMINATED","sponsor":"SBI ALApharma Canada, Inc.","startDate":"2021-04-27","conditions":"Breast Neoplasm Female, Breast Cancer","enrollment":57},{"nctId":"NCT04482621","phase":"PHASE2","title":"Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","status":"SUSPENDED","sponsor":"Johns Hopkins University","startDate":"2020-09-14","conditions":"COVID-19","enrollment":33},{"nctId":"NCT05177107","phase":"PHASE2","title":"Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis","status":"TERMINATED","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2021-11-24","conditions":"Osteomyelitis, Diabetic Foot Osteomyelitis","enrollment":41},{"nctId":"NCT05690048","phase":"PHASE2","title":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)","status":"RECRUITING","sponsor":"Michael Dill","startDate":"2025-07-16","conditions":"Immunotherapy, HCC - Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT06890039","phase":"PHASE2","title":"A-TANGO Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Yaqrit Ltd","startDate":"2025-09-01","conditions":"Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic","enrollment":78},{"nctId":"NCT06375811","phase":"PHASE3","title":"Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-03-16","conditions":"Infertility, Endometriosis","enrollment":297}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo + Standard of Care"],"phase":"phase_3","status":"active","brandName":"Placebo + SOC","genericName":"Placebo + SOC","companyName":"101 Therapeutics","companyId":"101-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}